SEC Form 4
Royalty Pharma plc (RPRX) insider trading
In the 12 months to Oct 26, 2026, 5 RPRX insiders reported open-market sales of $92.8M across 38 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $92.8M
- 38 filings · 5 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 38 of 38
- All $92.8M sold was pre-arranged
Who traded RPRX, and when
- Sale
- Sale, pre-arranged (10b5-1)
RPRX daily close from Oct 27, 2025 to Oct 26, 2026, between $36.41 and $64.68, last $64.68. 38 sale and 0 purchase filings by 5 insiders, marked at their filing dates. Terrance P. Coyne, EVP & CFO: sold $39.0M across 14 filings, first filed Nov 19, 2025, last Aug 17, 2026. Christopher Hite, EVP & Chairman, Partnering: sold $27.4M across 4 filings, first filed Jun 25, 2026, last Sep 24, 2026. George W. Lloyd, EVP, Investments & CLO: sold $13.8M across 3 filings, first filed Nov 21, 2025, last Dec 19, 2025. Marshall Urist, EVP, Research & Investments: sold $12.5M across 16 filings, first filed Dec 3, 2025, last Oct 5, 2026. Gregory Norden, Director: sold $161.4K across 1 filing, first filed May 15, 2026, last May 15, 2026.
Largest mark · tap a row for others
Terrance P. Coyne · EVP & CFO
Sale $10,360,814
243,541 shares
Filed Feb 4, 2026 · traded Feb 2
Pre-arranged (10b5-1) · close on filing date $43.68
Terrance P. Coyne · EVP & CFO
EVP & CFO
$39.0M soldChristopher Hite · EVP & Chairman, Partnering
EVP & Chairman, Partnering
$27.4M soldGeorge W. Lloyd · EVP, Investments & CLO
EVP, Investments & CLO
$13.8M soldMarshall Urist · EVP, Research & Investments
EVP, Research & Investments
$12.5M soldGregory Norden · Director
Director
$161.4K soldOpen-market trades
38 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Terrance P. Coyne | EVP & CFO | $39.0M | — | 14 | 100% of sales | |
| Christopher Hite | EVP & Chairman, Partnering | $27.4M | — | 4 | 100% of sales | |
| George W. Lloyd | EVP, Investments & CLO | $13.8M | — | 3 | 100% of sales | |
| Marshall Urist | EVP, Research & Investments | $12.5M | — | 16 | 100% of sales | |
| Gregory Norden | Director | $161.4K | — | 1 | 100% of sales |
| Filed | Insider | Type | Shares | Value | Held after | Source |
|---|---|---|---|---|---|---|
traded | Marshall Urist EVP, Research & Investments | SalePre-arranged (10b5-1) | 4,126 ordinary shares | $235.6K | 0 | |
traded | Marshall Urist EVP, Research & Investments | SalePre-arranged (10b5-1) | 4,126 ordinary shares | $238.8K | 4,126 | |
traded | Christopher Hite EVP & Chairman, Partnering | SalePre-arranged (10b5-1) | 100,000 ordinary shares | $5.9M | 274,328 | |
traded | Christopher Hite EVP & Chairman, Partnering | SalePre-arranged (10b5-1) | 100,000 ordinary shares | $6.0M | 370,401 | |
traded | Terrance P. Coyne EVP & CFO | SalePre-arranged (10b5-1) | 11,002 ordinary shares | $645.6K | 1,772 | |
traded | Christopher Hite EVP & Chairman, Partnering | SalePre-arranged (10b5-1) | 130,000 ordinary shares | $7.3M | Multiple accounts | |
traded | Marshall Urist EVP, Research & Investments | SalePre-arranged (10b5-1) | 9,099 ordinary shares | $508.5K | 0 | |
traded | Christopher Hite EVP & Chairman, Partnering | SalePre-arranged (10b5-1) | 150,000 ordinary shares | $8.2M | 676,991 | |
traded | Marshall Urist EVP, Research & Investments | SalePre-arranged (10b5-1) | 9,098 ordinary shares | $502.1K | 9,099 | |
traded | Terrance P. Coyne EVP & CFO | SalePre-arranged (10b5-1) | 64,399 ordinary shares | $3.5M | 0 | |
traded | Marshall Urist EVP, Research & Investments | SalePre-arranged (10b5-1) | 13,684 ordinary shares | $721.8K | 18,197 | |
traded | Gregory Norden Director | SalePre-arranged (10b5-1) | 3,045 ordinary shares | $161.4K | 191,803 | |
traded | Marshall Urist EVP, Research & Investments | SalePre-arranged (10b5-1) | 13,684 ordinary shares | $726.1K | 31,881 | |
traded | Terrance P. Coyne EVP & CFO | SalePre-arranged (10b5-1) | 34,791 ordinary shares | $1.7M | Multiple accounts | |
traded | Terrance P. Coyne EVP & CFO | SalePre-arranged (10b5-1) | 34,791 ordinary shares | $1.7M | Multiple accounts | |
traded | Terrance P. Coyne EVP & CFO | SalePre-arranged (10b5-1) | 34,791 ordinary shares | $1.6M | Multiple accounts | |
traded | Terrance P. Coyne EVP & CFO | SalePre-arranged (10b5-1) | 34,791 ordinary shares | $1.6M | Multiple accounts | |
traded | Terrance P. Coyne EVP & CFO | SalePre-arranged (10b5-1) | 34,791 ordinary shares | $1.6M | Multiple accounts | |
traded | Terrance P. Coyne EVP & CFO | SalePre-arranged (10b5-1) | 243,541 ordinary shares | $10.4M | Multiple accounts | |
traded | Marshall Urist EVP, Research & Investments | SalePre-arranged (10b5-1) | 20,000 ordinary shares | $821.8K | 0 | |
traded | Marshall Urist EVP, Research & Investments | SalePre-arranged (10b5-1) | 20,000 ordinary shares | $805.1K | 20,000 | |
traded | Terrance P. Coyne EVP & CFO | SalePre-arranged (10b5-1) | 69,582 ordinary shares | $2.7M | Multiple accounts | |
traded | Marshall Urist EVP, Research & Investments | SalePre-arranged (10b5-1) | 20,000 ordinary shares | $790.3K | 40,000 | |
traded | Marshall Urist EVP, Research & Investments | SalePre-arranged (10b5-1) | 20,000 ordinary shares | $815.6K | 60,000 | |
traded | Terrance P. Coyne EVP & CFO | SalePre-arranged (10b5-1) | 69,582 ordinary shares | $2.7M | Multiple accounts | |
traded | Marshall Urist EVP, Research & Investments | SalePre-arranged (10b5-1) | 20,000 ordinary shares | $769.7K | 80,000 | |
traded | Marshall Urist EVP, Research & Investments | SalePre-arranged (10b5-1) | 20,000 ordinary shares | $786.4K | 100,000 | |
traded | Marshall Urist EVP, Research & Investments | SalePre-arranged (10b5-1) | 20,000 ordinary shares | $767.6K | 120,000 | |
traded | George W. Lloyd EVP, Investments & CLO | SalePre-arranged (10b5-1) | 110,000 ordinary shares | $4.2M | 0 | |
traded | Terrance P. Coyne EVP & CFO | SalePre-arranged (10b5-1) | 69,582 ordinary shares | $2.7M | Multiple accounts | |
traded | Marshall Urist EVP, Research & Investments | SalePre-arranged (10b5-1) | 20,000 ordinary shares | $766.4K | 140,000 | |
traded | Marshall Urist EVP, Research & Investments | SalePre-arranged (10b5-1) | 41,576 ordinary shares | $1.6M | Multiple accounts | |
traded | George W. Lloyd EVP, Investments & CLO | SalePre-arranged (10b5-1) | 110,000 ordinary shares | $4.4M | 110,000 | |
traded | Terrance P. Coyne EVP & CFO | SalePre-arranged (10b5-1) | 69,582 ordinary shares | $2.8M | Multiple accounts | |
traded | Marshall Urist EVP, Research & Investments | SalePre-arranged (10b5-1) | 41,575 ordinary shares | $1.7M | Multiple accounts | |
traded | Terrance P. Coyne EVP & CFO | SalePre-arranged (10b5-1) | 69,582 ordinary shares | $2.7M | Multiple accounts | |
traded | George W. Lloyd EVP, Investments & CLO | SalePre-arranged (10b5-1) | 135,426 ordinary shares | $5.2M | Multiple accounts | |
traded | Terrance P. Coyne EVP & CFO | SalePre-arranged (10b5-1) | 69,594 ordinary shares | $2.7M | Multiple accounts |
Shares are as filed (ordinary shares or ADS); values are as converted to US$ in the filing.
GET /stocks/filings/vX/form-4?tickers=RPRX&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"RPRX"
],
"issuer_cik": "0001802768",
"owner_cik": "0001838139",
"accession_number": "0001838139-26-000028",
"form_type": "4",
"filing_date": "2026-10-05",
"period_of_report": "2026-10-05",
"issuer_name": "Royalty Pharma plc",
"issuer_trading_symbol": "RPRX",
"owner_name": "Urist Marshall",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "EVP, Research & Investments",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Class A Ordinary Shares",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-05",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 4126,
"transaction_price_per_share": 57.1,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 0,
"transaction_value": 235594.6,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on June 26, 2026."
}
],
"remarks": "In addition to the Class A Ordinary Shares disclosed above, the Reporting Person and family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 2,444,120 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd (\"RPH\") exchangeable into 1,356,528 Class A Ordinary Shares. Class E Ordinary Shares of RPH are subject to vesting conditions."
},
{
"tickers": [
"RPRX"
],
"issuer_cik": "0001802768",
"owner_cik": "0001838139",
"accession_number": "0001838139-26-000026",
"form_type": "4",
"filing_date": "2026-09-30",
"period_of_report": "2026-09-28",
"issuer_name": "Royalty Pharma plc",
"issuer_trading_symbol": "RPRX",
"owner_name": "Urist Marshall",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "EVP, Research & Investments",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Class A Ordinary Shares",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-09-28",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 4126,
"transaction_price_per_share": 57.88,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 4126,
"transaction_value": 238812.88,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on June 26, 2026."
}
],
"remarks": "In addition to the Class A Ordinary Shares disclosed above, the Reporting Person and family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 2,444,120 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd (\"RPH\") exchangeable into 1,356,528 Class A Ordinary Shares. Class E Ordinary Shares of RPH are subject to vesting conditions."
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 31 records
- Grants and awards29 records
- Gifts1 record
- Other1 record
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Royalty Pharma plc's CEO sold stock?
No. Pablo G. Legorreta (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is RPRX’s insider data?
These are RPRX Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track RPRX insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for RPRX every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.